In recent trading session, UroGen Pharma Ltd (NASDAQ:URGN) saw 2.69 million shares changing hands at last check today with its beta currently measuring 0.59. Company’s recent per share price level of $7.71 trading at -$2.14 or -21.77% at last check today assigns it a market valuation of $355.28M. That most recent trading price of URGN’s stock is at a discount of -168.48% from its 52-week high price of $20.70 and is indicating a discount of -15.95% from its 52-week low price of $8.94.
For UroGen Pharma Ltd (URGN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
UroGen Pharma Ltd (NASDAQ:URGN) trade information
Upright in the red during last session for losing -21.77%, in the last five days URGN remained trading in the red while hitting it’s week-highest on Tuesday, 05/13/25 when the stock touched $7.71 price level, adding 34.27% to its value on the day. UroGen Pharma Ltd’s shares saw a change of -27.65% in year-to-date performance and have moved -25.77% in past 5-day. UroGen Pharma Ltd (NASDAQ:URGN) showed a performance of -25.84% in past 30-days.
Wall Street analysts have assigned a consensus price target of 40 to the stock, which implies a rise of 80.73% to its recent value today. Analysts have been projecting 22 as a low price target for the stock while placing it at a high target of 60. It follows that stock’s current price would drop -185.34% in reaching the projected high whereas dropping to the targeted low would mean a loss of -185.34% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.39% during past 5 years.
UroGen Pharma Ltd (NASDAQ:URGN)’s Major holders
RTW INVESTMENTS, LP is the top institutional holder at URGN for having 3.56 million shares of worth $59.69 million. And as of 2024-06-30, it was holding 9.661 of the company’s outstanding shares.
The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 3.3 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.9621 of outstanding shares, having a total worth of $55.37 million.
On the other hand, iShares Trust-iShares Russell 2000 ETF and Fidelity Salem Street Trust-Fidelity Small Cap Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 998.29 shares of worth $7.78 million or 2.17% of the total outstanding shares. The later fund manager was in possession of 382.87 shares on Feb 28, 2025 , making its stake of worth around $2.98 million in the company or a holder of 0.83% of company’s stock.
